1. [Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?]
- Author
-
J.L. Pujol, B. Roch, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Programmed cell death ,Phase iii trials ,Maintenance ,Remission ,Immunothérapie ,medicine.medical_treatment ,Disease ,Deuxième ligne ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,03 medical and health sciences ,0302 clinical medicine ,Programmed cell death 1 ,Medicine ,Stage (cooking) ,Second line ,Small cell lung cancer ,biology ,business.industry ,Agents immuno-oncologiques ,Immunotherapy ,3. Good health ,Immuno-oncological agents ,030104 developmental biology ,Clinical research ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Cancer à petites cellules ,Non small cell ,business - Abstract
International audience; In the setting of small cell lung cancer (SCLC), the development of immuno-oncological agents, particularly those targeting Programmed cell Death protein 1 (PD-1) and Programmed cell Death protein Ligand 1 (PD-L1), is still at an early stage. Two critical elements need to be considered : the current data are extracted from Phase I and Phase II trials and the level of evidence from phase III trials has not been reached as it has been for non-small cell lung cancer (NSCLC) or for malignant melanoma ; The second aspect is the slow development of predictive factors for response to the immuno-oncological agents targeting the PD-1 receptor and its ligand. The clinical data are still too fragmentary to produce recommendations, although the improvement in progression-free survival seen in different phase II studies is promising. The expectation of clinicians dealing withSCLC is an indication of the challenge that this disease currently poses to oncology and justifies a focused clinical research effort.
- Published
- 2018